Inecalcitol, an analog of 1,25D₃, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system

Transcription, Genetic Antineoplastic Agents Apoptosis X-Linked Inhibitor of Apoptosis Protein Cell Cycle Checkpoints Inhibitor of Apoptosis Proteins 3. Good health Enzyme Activation Disease Models, Animal Mice 03 medical and health sciences 0302 clinical medicine Alkynes Caspases Cell Line, Tumor Carcinoma, Squamous Cell Animals Drug Screening Assays, Antitumor Vitamin D Cell Proliferation Cholecalciferol
DOI: 10.4161/cc.23846 Publication Date: 2013-02-22T10:37:03Z
ABSTRACT
Epidemiological data suggest an important role of vitamin D signaling in cancer development and progression, experimental studies demonstrate that the active metabolite 1α, 25-dihydroxyvitamin D₃ (1,25D₃) has broad spectrum antitumor activity. Hypercalcemia often been suggested to limit clinical application these data. The 14-epi-analog 1,25D₃, inecalcitol [19-nor-14-epi-23-yne-1,25-(OH)₂D₃; TX522], was developed have superagonistic activities but low hypercalcemia potential. We examined activity underlying mechanisms a murine squamous cell carcinoma (SCC) model system. In vitro, compared with showed enhanced receptor (VDR)-mediated transcriptional Inecalcitol suppressed SCC proliferation dose-dependent manner IC50 value 30 times lower than 1,25D₃. Both 1,25D₃ induced comparable level G0/G₁ cycle arrest cells. apoptosis by markedly higher Apoptosis mediated through activation caspase 8/10- 3 pathway. Further, inhibited mRNA protein expression c-IAP1 XIAP vivo, inhibits tumor growth fashion. Notably, significantly xenograft model. While vitro demonstrates apparent VDR binding antiproliferative effects vivo advantages disappear; at doses equivalent effects, similar is seen. This may be explained pharmacokinetics vs. attributed much shorter serum half-life inecalcitol.We show potent system, this associated strong induction apoptosis. These findings support further treatment.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (29)
CITATIONS (35)